User login
Article Type
Changed
Fri, 01/04/2019 - 11:12
Display Headline
Idarucizumab given the nod as the first specific antidote for an oral anticoagulant
In the fall of 2015, idarucizumab became the first drug-specific antidote to an oral anticoagulant to receive regulatory approval from the US Food and Drug Administration. Anticoagulants are designed to inhibit the formation of blood clots and prevent thrombotic disorders, but they can increase bleeding risk in patients who experience trauma or illness or who undergo invasive surgical procedures. For this reason, traditional anticoagulants have antidotes that reverse their therapeutic effects, but newer oral anticoagulants lack specific reversal agents and that has proven a barrier to their use in patients with higher bleeding risk.
Click on the PDF icon at the top of this introduction to read the full article.
Article PDF
Issue
The Journal of Community and Supportive Oncology - 14(1)
Topics
Page Number
8-10
Legacy Keywords
venous thromboembolism, VTE, deep venous thrombosis, pulmonary embolism, idarucizumab, humanized monoclonal antibody fragment, reversal agent, thrombin, direct oral anticoagulants, DOACs, dabigatran, rivaroxaban, apixaban, edoxaban, andexanet alfa
Sections
Article PDF
Article PDF
In the fall of 2015, idarucizumab became the first drug-specific antidote to an oral anticoagulant to receive regulatory approval from the US Food and Drug Administration. Anticoagulants are designed to inhibit the formation of blood clots and prevent thrombotic disorders, but they can increase bleeding risk in patients who experience trauma or illness or who undergo invasive surgical procedures. For this reason, traditional anticoagulants have antidotes that reverse their therapeutic effects, but newer oral anticoagulants lack specific reversal agents and that has proven a barrier to their use in patients with higher bleeding risk.
Click on the PDF icon at the top of this introduction to read the full article.
In the fall of 2015, idarucizumab became the first drug-specific antidote to an oral anticoagulant to receive regulatory approval from the US Food and Drug Administration. Anticoagulants are designed to inhibit the formation of blood clots and prevent thrombotic disorders, but they can increase bleeding risk in patients who experience trauma or illness or who undergo invasive surgical procedures. For this reason, traditional anticoagulants have antidotes that reverse their therapeutic effects, but newer oral anticoagulants lack specific reversal agents and that has proven a barrier to their use in patients with higher bleeding risk.
Click on the PDF icon at the top of this introduction to read the full article.
Issue
The Journal of Community and Supportive Oncology - 14(1)
Issue
The Journal of Community and Supportive Oncology - 14(1)
Page Number
8-10
Page Number
8-10
Topics
Article Type
Display Headline
Idarucizumab given the nod as the first specific antidote for an oral anticoagulant
Display Headline
Idarucizumab given the nod as the first specific antidote for an oral anticoagulant
Legacy Keywords
venous thromboembolism, VTE, deep venous thrombosis, pulmonary embolism, idarucizumab, humanized monoclonal antibody fragment, reversal agent, thrombin, direct oral anticoagulants, DOACs, dabigatran, rivaroxaban, apixaban, edoxaban, andexanet alfa
Legacy Keywords
venous thromboembolism, VTE, deep venous thrombosis, pulmonary embolism, idarucizumab, humanized monoclonal antibody fragment, reversal agent, thrombin, direct oral anticoagulants, DOACs, dabigatran, rivaroxaban, apixaban, edoxaban, andexanet alfa
Sections
Citation Override
JCSO 2016;14:8-1
Disallow All Ads
Alternative CME
Article PDF Media
Document